Main Products/ Services/ Pipelines & Platforms
OBI Pharma, Inc., is a Taiwan biopharmaceutical company publicly-listed on the Taipei Exchange (TPex ticker: 4174). OBI’s mission is to develop and license novel therapeutic agents for unmet medical needs against cancer targets such as Globo Series (incl. Globo H, SSEA3, SSEA4) and AKR1C3. Globo Series and AKR1C3 are highly expressed in cancers of unmet need including Breast, Ovarian, Gastric, Lung, Liver Prostate and Esophageal. The company’s novel first-in-class oncology portfolio includes: Adagloxad Simolenin (formerly OBI-822; Globo H cancer vaccine) OBI-888 (Globo H mAb) OBI-999 (Globo H ADC) OBI-866 (SSEA4 cancer vaccine) OBI-3424 (small-molecule prodrug targeting AKR1C3 enzyme)
▪ OBI is seeking out-licensing opportunities to expedite the clinical development of our pipeline products. ▪ OBI is also looking to in-license novel anti-cancer therapies to compliment and strengthen our pipeline.
Executive Director, Business Development